Rationale and design for the CARDIOVIT Study (Cardiovit, Atherosclerotic vascular disease and hypeRhomocysteinemia: An epiDemiological study in Indians, additionally evaluating the effect of Oral VITamin supplementation)

Current Medical Research and Opinion

Volumn 22, Issue 4, 2006, Pages 641-648

  Shenoy, K T ^a   Lena, K B ^a   Sali, N ^a   Syam, S ^a   Shenoy, S T ^a   Rajadhyaksha, V D ^b   Pai, G P ^b   Shaikh, A A ^b  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b PFIZER INC   (United States)

Author keywords

Cardiovascular diseases; Epidemiology; Folic acid; Homocysteine; India

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CARDIOVIT; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; MULTIVITAMIN; PLACEBO; PYRIDOXINE; RETINOL; SELENIUM; UNCLASSIFIED DRUG;

ANAMNESIS; ATHEROSCLEROSIS; CLINICAL EXAMINATION; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE; ETHICS; HUMAN; HYPERHOMOCYSTEINEMIA; INDIAN; LABORATORY TEST; MEDICAL PRACTICE; METHODOLOGY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUTRITIONAL STATUS; PHYSICAL ACTIVITY; PREVALENCE; RISK FACTOR; SOCIOECONOMICS; STATISTICAL ANALYSIS; UNIVARIATE ANALYSIS; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

ADULT; ANTIOXIDANTS; ATHEROSCLEROSIS; CROSS-SECTIONAL STUDIES; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INDIA; MALE; MIDDLE AGED; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME; VITAMIN B COMPLEX; VITAMINS;

EID: 33646252932     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X96344     Document Type: Conference Paper

References (37)

1. Reddy NK, Kumar DN, Rayudu NV, et al. Prevalence of risk factors for coronary atherosclerosis in a cross-sectional population of Andhra Pradesh. Indian Heart J 2002;54:697-701
2. Misra A. Atherosclerosis in Indians and lipoprotein (a). J Assoc Physicians India 1999;47:313-7
3. Puri A, Gupta OK, Dwivedi RN, et al. Homocysteine and lipid levels in young patients with coronary artery disease. J Assoc Physicians India 2003;51:681-5
4. Goel PK, Bharti BB, Pandey CM, et al. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease. Indian Heart J 2003;55:234-40
5. Balaranmjan R. Ethnicity and variations in mortality from coronary heart disease. Health Trends 1996;28:45-51
6. McKeigue PM, Shah B, Mermott MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991;337:382-8
7. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000;356:279-84
8. Butz LW, du Vigneaud V. The formation of a homologue of cystine by the decomposition of methionine with sulfuric acid. J Biol Chem 1932;99:135-42
9. Green R, Jacobsen DW. Clinical implications of hyperhomocysteinemia. In: Bailey LB, editor. Folate in health and disease. New York: Marcel Dekker; 1995. p. 75-122
10. Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet, and cardiovascular diseases: a statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation 1999;99:178-82
11. Prasad K. Homocysteine, a risk factor for cardiovascular disease. Int J Angiology 1999;8:76-86
12. Boushey CJ, Beresford SA, Omen GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. J Am Med Assoc 1995;274:1049-57
13. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications on prevention. Arch Internal Med 1998;158:862-7
14. McCully KS. Homocysteine and vascular disease. Nat Med 1996;2:386-9
15. Graham IM, Daly LE, Refsum H, et al. Plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1997;277:1775-81
16. Ueland PM, Refsum H. Plasma homocysteine - a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 1989;114:473-501
17. Chambers JC, Obeid OA, Refsum H, et al. Plasma homocysteine concentrations and risk of coronary heart diseases in UK Indian Asian and European men. Lancet 2000;355:523-7
18. Refsum H, Yajnik CS, Gadkari M, et al. Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians. Am J Clin Nutr 2001;74:233-41
19. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scan J Clin Lab Invest 1988;48:215-21
20. Saltzman E, Mason JB, Jacques PF, et al. B vitamin supplementation lowers homocysteine levels in heart disease [abstract]. Clin Res 1994;42:172A
21. 6 on clinical outcome after percutaneous coronary intervention. J Am Med Assoc 2002;288:973-9
22. Brouwer IA, van Dusseldorp M, Thomas CMG, et al. Low-dose folic acid supplementation decreases plasma homocysteine concentration: a randomized trial. Am J Clin Nutr 1999;69:99-104
23. 12. Am J Cardiol 1999;83:821-5
24. Nallamothu BK, et al. Homocysteine and coronary heart disease. Pharmacoeconomics 2002;20:429-42
25. Bostom AG, Selhub J. Homocysteine and arteriosclerosis: subclinical and clinical disease associations. Circulation 1999;99:2361-3
26. Bostom AG, Garber C. Endpoints for homocysteine - lowering trials. Lancet 2000;355:511-2
27. THcy Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Br Med J 1998;316:894-8
28. Hazra A, Tripathi SK. Folic acid revisited. Indian J Pharmacol 2001;33:322-42
29. Questionnaire based assessment - physical inactivity in WHO STEPwise approach to NCD surveillance - final draft, World Health Organisation; 2001
30. Emsley AM, Plane F, Jackson CL, et al. Oxidant stress, nitric oxide, and transition metals in homocysteinemic angiopathy: novel mechanisms. Vascular Disease 1998;1:66-72
31. Riddell LJ, Chisholm A, Williams S, Mann JI. Dietary strategies for lowering homocysteine concentrations. Am J Clin Nutr 2000;71:1448-54
32. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. New Engl J Med 1999;340:1449-54
33. Misra A, Vikram N, Dwivedi M, et al. High homocysteine levels in healthy people belonging to upper-middle and lower socio-economic strata in New Delhi [All India Institute of Medical Sciences, New Delhi] J Assoc Physicians India 2002;50:211 [abstract]
34. Puri A, Gupta O, Dwivedi R, et al. Homocysteine in patients under 45 years of age with coronary insufficiency, PGIM, Kanpur. J Assoc Physicians India 2002;50:63[abstract]
35. Robinson K. Homocysteine and coronary artery disease. In: Carmel R, Jacobson DW, editors. Homocysteine in health and disease. Cambridge: Cambridge University press; 2001
36. Bonna KH; on behalf of the NORVIT study group. Randomised trial of homocysteine-lowering with B vitamins for secondary prevention of cardiovascular disease after acute myocardial infarction. The Norwegian Vitamin Study (NORVIT). Available from: http://www.escardio.org [last accessed on 20 Jan 2006]
37. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-13